Dr Mark A Feldkamp, DO | |
1094 220th St, Jesup, IA 50648-9400 | |
(319) 827-3000 | |
(319) 827-2393 |
Full Name | Dr Mark A Feldkamp |
---|---|
Gender | Male |
Speciality | Family Practice |
Experience | 27 Years |
Location | 1094 220th St, Jesup, Iowa |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1437198991 | NPI | - | NPPES |
4178616 | Medicaid | IA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 03160 (Iowa) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Allen Hospital | Waterloo, IA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Iowa Physicians Clinic Medical Foundation | 8729992318 | 972 |
News Archive
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers from the Center for Disease Dynamics, Economics & Policy, USA, and Johns Hopkins University, USA, found evidence to support the notion that increased humidity may have contributed to lesser cases in spring earlier this year (2020). However, as the winter season fast approaches, the researchers fear that the decreasing humidity is likely to lead to an increase in COVID-19 cases.
Biovail Corporation today announced top-line results from ACADIA Pharmaceutical Inc.'s first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.
› Verified 5 days ago
Entity Name | Iowa Physicians Clinic Medical Foundation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1366425274 PECOS PAC ID: 8729992318 Enrollment ID: O20031118000363 |
News Archive
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers from the Center for Disease Dynamics, Economics & Policy, USA, and Johns Hopkins University, USA, found evidence to support the notion that increased humidity may have contributed to lesser cases in spring earlier this year (2020). However, as the winter season fast approaches, the researchers fear that the decreasing humidity is likely to lead to an increase in COVID-19 cases.
Biovail Corporation today announced top-line results from ACADIA Pharmaceutical Inc.'s first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Mark A Feldkamp, DO 2101 Kimball Ave, Ll14, Waterloo, IA 50702-5063 Ph: (319) 272-1590 | Dr Mark A Feldkamp, DO 1094 220th St, Jesup, IA 50648-9400 Ph: (319) 827-3000 |
News Archive
BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
A team of researchers from the Center for Disease Dynamics, Economics & Policy, USA, and Johns Hopkins University, USA, found evidence to support the notion that increased humidity may have contributed to lesser cases in spring earlier this year (2020). However, as the winter season fast approaches, the researchers fear that the decreasing humidity is likely to lead to an increase in COVID-19 cases.
Biovail Corporation today announced top-line results from ACADIA Pharmaceutical Inc.'s first pivotal Phase III trial with pimavanserin in patients with Parkinson's disease psychosis, or PDP.
Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced that Bayer Schering Pharma AG has exercised its option under the option, collaboration and license agreement entered into on January 12, 2009 to develop a new BiTE antibody for the treatment of solid tumors.
› Verified 5 days ago